Atlas
Back to RCM
Founder / Operator·RCM

Michal Miernowski

CEO and Co-Founder at Amperos Health

New York, New York, United States

MM
LinkedIn
Why they matter

Ex-Goldman, Onex and Ardea healthcare investor now operating the RCM asset Bessemer just backed; he reads provider-payer economics from both the underwriting and operator seat.

Background

Michal Miernowski is co-founder and CEO of Amperos Health, a New York-based AI-native denial management and revenue recovery company he started in 2023 with CPO Alvin Wu (ex-Samsara, Fitbit) and CTO Wilson Wang. He came to the problem from the capital side: analyst in Goldman Sachs' Financial Institutions Group covering insurance, then a Senior Associate at Onex Partners evaluating financial, business and healthcare services investments, then Vice President at Ardea Partners leading deal teams across healthcare, technology and business services. Working alongside clinic administrators as an investor is what surfaced the manual-billing bottleneck Amperos now automates.

Notable deals

  • 2026
    Raised $16M Series A led by Bessemer Venture Partners (Uncork Capital, Neo participating) and launched Amperos' AI-native, end-to-end denial management and revenue recovery platform
  • 2025
    Raised $4.2M seed led by Uncork Capital, Neo and Nebular with angels from OpenAI, Twilio and Stripe; AI agent 'Amanda' had automated 75,000+ payer calls and collected $120M in annual revenue for customers
  • 2026
    Scaled Amperos to 3,000+ clinical locations across all 50 states, recovering nearly $700M annually across 500,000+ claims, with denials resolved 5x faster and up to 50% lower cost than outsourced vendors
  • 2026
    Selected by Bessemer as its agentic-AI bet on healthcare's $260B+ denial management problem; BVP published its investment thesis citing the founding team's finance, product and AI mix

Call-prep brief

Background

  • Co-founded Amperos Health in 2023 with Alvin Wu (CPO, ex-Samsara/Fitbit) and Wilson Wang (CTO). Based in New York.
  • Prior career is entirely buy/sell side: Goldman Sachs FIG (insurance coverage), Onex Partners (financial, business and healthcare services), then VP at Ardea Partners running healthcare/tech/business services deal teams. He speaks in ROI and cost-to-collect, not clinical workflow.

Current focus

  • End-to-end agentic denial management: LLM agents with computer and voice capability navigate payer portals, call insurers, and file corrected claims and appeals, with human subject-matter experts held back for nuanced cases.
  • Scale today: 3,000+ clinical locations, all 50 states, 500,000+ claims, ~$700M recovered annually. Claims 70% denial-rate reduction and 5x faster resolution.

What he cares about

  • Provable per-claim ROI. Prices as a subscription on claim volume rather than contingency, explicitly so ROI holds at any practice size.
  • Stated ambition is to become "the AI-native infrastructure layer between providers and payers" and move upstream into denial *prevention*.
  • Operating philosophy he volunteers: pick the top 2-3 things that matter over 6-12 months and put all time and money there.

Recent moves

  • April 2026: $16M Series A led by Bessemer, following a $4.2M seed in June 2025.

Potential sensitivities

  • He is displacing PE-owned outsourced RCM vendors on price. A PE call can read as competitive diligence; be explicit about intent.
  • Freshly funded, so a capital-first framing lands flat.
  • Voice agents calling payers is regulatorily and reputationally delicate. Customer names beyond DOCS Dermatology are likely confidential.

Ask him

  1. What share of denials clears fully autonomously today, and is that ratio improving by customer cohort or plateauing?
  2. Volume-based subscription vs contingency: how does the model hold when a provider's denial rate drops 70% and billable volume falls with it?
  3. Which payers and specialties does agentic automation still break on, and what EHR-side access does upstream denial prevention actually require?

Outreach draft

Subject
Denial economics from both sides
Michal, I look at healthcare RCM from the investor side and have been following Amperos since the Bessemer round. What interests me is less the raise than the underwriting question behind it: whether agentic denial resolution genuinely compresses cost-to-collect enough to displace outsourced vendors, or simply re-prices them. Having sat at Onex and Ardea before taking the operator seat, you have seen both sides of that math, which is rare. I am not pitching capital. I would value 30 minutes on where autonomy holds across payers and specialties today, and where it still breaks. Happy to work entirely around your calendar. Best, [Your Name]

Linked companies

Sources

Strongest evidenceStructured data8 public sourcesVerified2026-08-03How the grades work